NCT03128164View on ClinicalTrials.gov

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

PHASE1CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

August 8, 2017

Primary Completion Date

August 2, 2023

Study Completion Date

August 2, 2023

Conditions

Lymphomas

Interventions

DRUG

HMPL-689

Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.

Trial Locations (3)

200032

Fudan University Shanghai Cancer Center, Shanghai

430030

TongJi Medical College Huazhong University of Science& Technology, Wuhan

510060

Sun Yat-sen University cancer center, Guangzhou

All Listed Sponsors

lead

Hutchison Medipharma Limited

INDUSTRY

NCT03128164 - A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed | Biotech Hunter | Biotech Hunter